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Abstract: Systemic sclerosis (SSc) is a rare disease, with unfavorable clinical course and prognosis,
characterized by progressive multisystemic involvement. SSc associated pulmonary hypertension
(SSc-PAH) and interstitial lung disease (ILD) are the most important factors for morbi-mortality in
these patients, being responsible for more than 60% of total deaths. Though pulmonary arterial
hypertension (PAH) is the dominant subtype seen in SSc, PH secondary to ILD, left-heart pathology,
and pulmonary veno-occlusive disease (PVOD) are also possible occurrences. Initial evaluation of a
SSc case is complex and should be performed with a multidisciplinary approach. Early detection
of SSc-PAH is imperative, given the fact that new and effective medications are available and early
treatment was shown to improve outcomes. Therefore, screening algorithms must be used adequately
and in a cost-effective manner. Sensitivity and negative predictive value (NPV) are the most important
performance measures in a screening test. Several algorithms were developed in the last decade (e.g.,
DETECT and ASIG) and demonstrated higher efficiency when compared to older algorithms. The
present manuscript details the risk factors for SSc-PAH and includes a critical description of current
detection algorithms, as a primer for clinicians working in the field of cardio-rheumatology.
Keywords: systemic sclerosis; pulmonary hypertension; screening; cardio-rheumatology
1. Introduction
Systemic sclerosis (SSc) is a rare disease, with unfavorable clinical course and prog-
nosis, characterized by progressive multisystemic involvement, which in the end causes
disability and death [1]. The reported prevalence of SSc is 7.2–33.9 and 13.5–44.3 per 100,000
individuals in Europe and North America, respectively [2]. This leads to an estimated case
load of 9–19/million in the United States, with close to 100,000 patients to date [1]. There is
female gender predominance (4.6/1), and although this condition can be diagnosed at any
age, the highest incidence is between 30 and 50 years [1].
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From a pathophysiological viewpoint, the triggering mechanism is unknown, yet there
is genetic predisposition and probably exposure to environmental factors: infectious, toxic,
drugs, occupational factors, etc., triggering autoimmunity and microvascular changes [1].
The natural history of SSc has two different stages: the initial phase is dominated by
micro-vasculopathy and sometimes also inflammatory manifestations, while the late stage,
which in some patients never develops, is mainly characterized by fibrosis of the skin and
internal organs [1]. Data from EUSTAR and a cohort of French death certificates of SSc
patients proved that primary heart disease is the main cause of death in SSc, explaining 30%
of SSc deaths, followed by respiratory causes related to interstitial lung disease (ILD) [3].
Therefore, SSc associated pulmonary arterial hypertension (PAH) (SSc-PAH) and ILD are
the most important factors for morbi-mortality in these patients, being responsible for more
than 60% of total deaths [4,5].
Two different subsets of SSc are described, according to the extent of skin fibrosis:
limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc), with certain immunologic profiles
and associated internal organ involvement [1]. Patients with lcSSc have immunology
characterized by anti-centromere antibodies (ACA), and more frequently develop PAH
as a late complication [1]. In contrast, patients with dcSSc usually have a more severe
disease course and are associated significantly higher rates of ILD [1]. Anti-topoisomerase
1 (Scl-70) and anti-RNA polymerase III antibodies are most frequently found in this subset
of patients [1].
Pulmonary hypertension (PH) encompasses a group of severe clinical entities in which
loss of and obstructive remodeling of the pulmonary vascular bed is responsible for the
rise in pulmonary arterial pressure and pulmonary vascular resistance (PVR), resulting
in progressive right heart failure and functional decline [6]. While normal values of mean
pulmonary artery pressure (mPAP) are considered to be 14 ± 3 mmHg, according to
the European Society of Cardiology (ESC)/European Respiratory Society (ERS) common
guidelines published in 2015, PH is defined as elevated mPAP more than 25 mmHg at rest,
measured by right heart catheterization (RHC) [7]. In addition to invasively determining
the mean pressure in the pulmonary artery, RHC identifies other hemodynamic parameters,
which further divide PH into two groups: pre-capillary and post-capillary [7]. Pre-capillary
PH is defined by pulmonary artery wedge pressure (PAWP) ≤15 mmHg and PVR ≥3 Wood
Units (W.U.) [7]. Post-capillary PH is associated with high PAWP >15 mmHg, but PVR can
vary: isolated postcapillary PH has PVR ≤3 W.U. and/or diastolic pressure gradient (DPG)
<7 mmHg, whilst PVR ≥3 W.U. and/or DPG ≥7 mmHg show the association between
post-capillary and pre-capillary PH [7].
The existence of pressure values in the “grey zone” (20–24 mmHg) was addressed by
an update in the definition of PH proposed at the 6th World Symposium on Pulmonary
Hypertension which includes a mPAP cut-off of 20 mmHg (not yet included in the guide-
lines) [8]. This dictates the necessity that patients with such mPAP and high risk of future
development of PH (connective tissue diseases (CTD), hereditary PAH) are to be kept
under close follow up [7].
2. Manuscript
2.1. SSc and PH
Clinical classification of PH includes five major groups, each one with its own sub-
types [7]. PAH associated with CTD is part of the first group (subclass 1.4 along with the
forms associated with HIV infection or portal hypertension). However, as a multisystemic
disorder, SSc can also generate other types of PH: derived from left-heart disease, secondary
to pulmonary causes or hypoxia, due to prothrombotic states, mainly if associated with
antiphospholipid antibodies [4] (Table 1).
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Table 1. Possible causes of PH in SSc. Legend: PAH–pulmonary arterial hypertension, PVOD–pulmonary veno-occlusive
disease, ILD–interstitial lung disease, DLCO–diffusing capacity for carbon monoxide, CTEPH–chronic thromboembolic
pulmonary hypertension.
Group PH Type Observations Ref
Group 1.4 Pulmonary arterial hypertension
Remodelling and constriction of the
pulmonary arteries and arterioles, with
progressive increase of the pulmonary
vascular resistance and right heart failure
[4,9–11]
Group 1 Pulmonary veno-occlusive disease
More pronounced venous/capillary
involvement; associated with poor prognosis,
limited response to PAH therapy which
increases risk of pulmonary oedema
[12–15]
Group 2 PH secondary to left heart disease
Myocardial fibrosis with diastolic
dysfunction, possible late systolic
dysfunction
[16]
Group 3 PH secondary to lung disease/hypoxia
SSc with ILD can lead to hypoxia depending






Prothrombotic state especially due to
antiphospholipid antibodies presence
[20,21]
A comprehensive differential diagnosis is essential in order to correctly classify PH, as
this is instrumental in establishing the appropriate therapeutic choices.
PAH prevalence in the population of SSc varies between 5–13% in multiple epidemi-
ologic studies, including a recent systematic review; conversely 30% of all PAH causes
are represented by CTD, mostly SSc [4,22,23]. DETECT, the first multicentric study using
systematic RHC in patients with SSc at increased risk for PH, found PAH in 19% of patients,
70% of whom had lcSSc [24]. ILD and left-sided heart disease are also responsible for
1–1.4%, and 1–1.3% of all cases, respectively [24].
Cardiovascular disease caused by SSc is not limited solely to the elevation of blood
pressure in the pulmonary circulation. Autoimmune disorders, in general, are associated
with high cardiovascular risk, SSc not representing an exception in this regard [25]. In the
setting of complex and multiple intense inflammatory chain reactions which these diseases
generate, atherosclerosis is accelerated, myocardial fibrosis is described in both left ventricle
(LV) and right ventricle (RV) with ensuing functional impairment, arrhythmogenesis is
present, and conduction disturbances alongside pericarditis may occur [25]. Therefore, PH
secondary to left heart disease is a likely occurrence.
Pulmonary veno-occlusive disease (PVOD) in SSc is very difficult to distinguish from
PAH Group 1.4 because of a similar initial clinical picture consisting of exertion dyspnoea,
fatigue and signs of heart failure [26]. However, oxygen saturation in the peripheral
blood is usually lower and auscultatory pulmonary rales are more frequently found in
PVOD and are associated with pulmonary oedema, especially after administration of
pulmonary vasodilators.
A prothrombotic state can also be found in SSc, especially if antiphospholipid an-
tibodies (aPL) are present, which was described in 10–24% of SSc patients in various
cohorts [27,28], with a median percentage of aPL-positive patients of 14% in a recent
systematic review [29].
Reported in a meta-analysis of 22 epidemiologic trials, the rate of survival in patients
with SSc-PAH is 93%, 88% and 75% at 1, 2 and 3 years, respectively and at 3 years mortality
rates reach 33%, representing, however, an improvement as compared to older cohorts due
to the evolution of targeted therapies [30]. Moreover, compared to idiopathic pulmonary
arterial hypertension (IPAH), SSc-PAH has worse outcomes because it does not respond as
well to pulmonary vasodilators, despite a lower mPAP and similar reductions in cardiac
index [4]. SSc-PAH is usually diagnosed several years after SSc discovery, and at the time
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of diagnosis most patients are classified in World Health Organization (WHO) functional
class III/IV, with consecutive high mortality [5,31]. This leads to the necessity of instituting
an early screening strategy in order to identify PH in patients with SSc, even asymptomatic
ones, and to initiate specific treatment strategies.
2.2. Risk Factors for SSc-PAH
Several registries including PHAROS (Pulmonary Hypertension Assessment and
Recognition of Outcomes in Scleroderma), REVEAL registry (Registry to Evaluate Early
and Long-Term Pulmonary Arterial Hypertension Disease Management) and the French
registry identified several risk factors for unfavorable clinical outcomes in patients with
SSc-PAH: age over 60 years, male gender, dcSSc, WHO IV functional class, low diffusing
capacity for carbon monoxide (DLCO) < 39%, systolic blood pressure (BP) ≤ 110 mmHg,
distance at 6 min walking test (6MWT) < 165 m, mean pressure in the right atrium (RA) >
20 mmHg, and PVR > 32 W.U. [32–35] (Table 2).
Table 2. Risk factors for PH development in SSc. Legend: WHO–World Health Organization, ESR-
erythrocyte sedimentation rate, 6MWT–six-minute walking test, DLCO-diffusing capacity for carbon
monoxide, RHC-right heart catheterization, RA–right atrium, SBP–systolic blood pressure, IgG–G
immunoglobulins, PVR–pulmonary vascular resistance, W.U.–Wood Units, ACA–anti-centromere
antibodies, RP–Raynaud’s Phenomenon.
Demographic Characteristics
>60 years old [32,33]
Male gender [32,33]
Clinical Factors
WHO functional class IV [33]
SBP ≤ 110 mmHg [33]
Digital ulcers [36]
Osteolysis of the distal phalanges [36]







6MWT <165 m [32,33]
Pulmonary Function Testing DLCO < 39% [32]
Right Heart Catheterization
Mean RA pressure > 20 mmHg [33]
PVR > 32 Wood Units [33]
Digital ulcers and osteolysis of the distal phalanges, even though not directly related
to PAH, appear to predict development of groups 2 and 3 of PH [36]. Long-term evolution
of Raynaud’s Phenomenon (RP) secondary to SSc also predisposes to PAH [22]. Presence
of telangiectasia is a supplementary risk factor for the occurrence of PH [24].
Laboratory tests can help the clinician anticipate PH and its specific subtype: erythro-
cyte sedimentation rate (ESR) and elevated G immunoglobulins (IgG) can be an indicator
for PH secondary to chronic lung disease or left-sided heart pathology [36]. Serum level
of ACA also heightens the risk, while the presence of aPL can raise awareness for the
occurrence of chronic thromboembolic pulmonary hypertension (CTEPH) [22,28].
Steen et al. demonstrated that a reduced DLCO is the best long-term predictor for
the development of PH in SSc [37,38]. Most frequently, at the time of diagnosis, DLCO is
significantly low (<50%) in the absence of coexistent ILD [37,38]. Steen et al. also found
that, in comparison with those without PH, lcSSc cases and PH had DLCO reduced by
52%, 5 years before the detection of the systemic pathology [37]. Moreover, several studies
showed that even 10 to 15 years before PH diagnosis, there was a marked decrease in
DLCO value, while forced vital capacity (FVC) remained normal or near-normal [37].
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2.3. Why Is Screening for SSc-PAH Important?
Pulmonary vasodilatory medication indicated for the treatment of PAH has signif-
icantly improved the prognosis for this category of patients [4]. Not only are there new
and effective medications available, but early treatment was proven to generate better
outcomes [39,40]. A multitude of clinical trials brought extra arguments for the utility of
screening because of the beneficial effects exerted by different compounds: ARIES 1 and
ARIES 2 (studies with endothelin antagonists) which evaluated patients with CTD and
PAH demonstrated the increase in distance at the 6MWT and reduction of adverse clinical
outcomes [41]. CTD associated PAH patients were also included in the SUPER and PHIRST
trials showing the benefits of sildenafil and tadalafil respectively on symptoms relief [42,43].
PATENT-2 demonstrated that riociguat (guanylate cyclase stimulator) also improves dis-
tance at 6MWT and functional class [44]. However, maybe the most interesting in this
regard is the GRIPHON trial (selexipag–prostacyclin analogue with oral administration)
that published data according to which all-cause mortality rates were reduced by 40% in
patients with PAH treated with this drug, especially early after diagnosis [45].
Because of pulmonary vasodilatory medication, survival rates of patients with SSc-
PAH have improved from 12 months (1996) to 3 years in 60% of cases nowadays [46].
Most importantly, data from the ItinerAir SSc cohort demonstrated that systematic PAH
detection programmes are able to identify those patients with milder disease and whose
long-term survival prospects are better, compared with cases diagnosed during routine
clinical practice [31,47]. Therefore, active PAH screening strategies are instrumental in
improving the prognosis for SSc patients.
2.4. Methods and Screening Algorithms for PH in SSc
Screening is defined as the systematic testing of asymptomatic individuals in or-
der to identify a certain pathology in the subclinical phase, or the testing of the mildly
symptomatic to prevent the progression of the already manifesting disease [31]. Implemen-
tation of a screening program is justified when rapid detection can lead to the initiation of
medication that can cure the patient or can modify the natural history of the disease [31].
2.4.1. Clinical Examination
In contemporary practice, regular, complete and systematic clinical examination still re-
mains fundamental. Unfortunately, excluding the typical features of SSc, in the early stages
SSc-PAH is scarce in signs/symptoms. Clinical findings may be present only when the ele-
vated pressure in the pulmonary artery causes the failure of the RV, which in turn can lead
to loud cardiac 2 sound, jugular a wave, turgescent jugular veins, holo/mezotele-systolic
heart murmur with maximum intensity in the tricuspid area, Graham-Steel murmur, and
peripheral oedema, making clinical screening strategies inefficient [25,46].
Several SSc-related clinical features can also represent predictors for PAH develop-
ment: digital ulcers, telangiectasia, and calcinosis [48].
2.4.2. Nailfold Capillaroscopy
The progression of capillary loss as well as the evolution towards a severe (active/late)
nailfold capillaroscopic pattern were found to be associated with incident SSc-PAH [49].
2.4.3. 6MWT
An objective, accurate when performed correctly, reproducible and cheap method
for detecting hypoxemia and worsening exertion levels in patients with PAH and SSc, the
6MWT was used as a marker of good outcomes in most clinical studies which evaluated
the benefit of pulmonary vasodilatory medication [22].
Although it identifies poor exercise tolerance, as well as oxygen desaturation in the
peripheral blood, it is not an adequate tool for PAH screening because it is neither sensible,
nor specific [22]. Although the 6MWT distance is used as a risk marker in a multitude
of screening algorithms, and small distances predict high rates of mortality, in patients
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with SSc it is not an appropriate outcome measurement when assessing for PAH, as it
may be influenced by various other factors such as concomitant myopathy, myositis or
arthritis [22,24].
2.4.4. Laboratory Biomarkers
Extended SSc antibody status provides a better disease characterization and brings
clues for possible SSc-related organ involvements, such as PAH. ACA are risk factors for
SSc-PAH and patients should be carefully monitored in case of positivity [50]. Moreover,
the inflammatory status might reflect the worsening of the disease. C-reactive protein
(CRP) levels higher than 8 mg/L were identified as an independent predictor for PAH poor
prognosis [35].
Biomarkers such as brain natriuretic peptide (BNP) and its N-terminal fragment
(NTproBNP) are objective tools for detecting cardiac dysfunction, irrespective of etiology.
However, the circulating levels of NTproBNP do not vary consistently across all types
of PAH: in CTD associated PAH their levels are high compared to IPAH, despite milder
hemodynamic disturbances [31].
Williams et al. reported a cut-off value of 395 pg/mL for NTproBNP, with 55.9%
sensitivity and 95.1% specificity for detecting SSc associated PAH [51]. Moreover, in a large
cohort of patients, using 125 ng/L concentration as a threshold value, NTproBNP reliably
and independently predicted 3-year mortality, with a sensitivity of 78.1% and a negative
predictive value (NPV) of 97.6%, respectively [52]. More recent studies also included
cardiac troponin as a prognostic biomarker, probably by reflecting myocardial injury due
to both SSc-related myocardial fibrosis, as well as PH-related myocardial stress [53].
Red cell distribution width (RDW) is a quantitative measure of circulating erythrocytes
size. In a prospective clinical trial consisting of 145 patients with SSc-PAH, Zhao et al.
demonstrated the presence of an independent association between RDW and PH both in
lcSSc and dcSSc [54]. RDW is inversely proportional to DLCO and its elevation can predict
the worsening of cardio-pulmonary function in patients with SSc [54].
Uric acid levels were shown to be elevated in chronic hypoxic states like obstructive
pulmonary disease or chronic heart failure. In SSc, determination of uric acid level together
with BP monitoring are recommended for the early detection of scleroderma crisis. More-
over, serum levels of uric acid are considered to be a biomarker for the severity of PH
related ventricular dysfunction [55].
2.4.5. Echocardiography
Annual echocardiography of SSc patients remains the cornerstone of PH screening.
By estimating pressures and measuring cavitary dimensions, volumes, systolic and dias-
tolic function parameters, echocardiography is able to detect all possible cardiovascular
complications of the disease. Moreover, it is the most efficient screening method because
it is non-invasive, cost-efficient and virtually readily available everywhere [31,56]. Thus,
European and American clinical practice guidelines recommend that patients with SSc are
to be evaluated by echocardiography even if they are asymptomatic [25].
Twenty-eight echocardiographic values have been ascertained in the DETECT study
(i.e., RA and RV areas, RA diameter, tricuspid regurgitation (TR) velocity, tricuspid annular
plane systolic excursion (TAPSE)), but only the velocity of the TR and areas of RA and RV
demonstrated utility in detecting PH [57].
Several echocardiographic abnormalities, when present, might indicate PH and thus
can be an incentive for referring the patient to RHC: systolic pulmonary artery pressure
(sPAP) ≥ 40 mmHg, TR velocity (TRV) >2.8 m/sec, RA dimensions > 53 mm and RV dimen-
sions > 35 mm [25]. If sPAP values < 36 mmHg and TRV < 2.8 m/s are not accompanied
by other echocardiographic signs suggestive of PH, then its presence is unlikely [24]. On
the other hand, velocity of regurgitation > 3.4 m/s and sPAP estimated over 50 mmHg are
strong indicators of high likelihood of PH [24]. Compared to RHC, echocardiography has a
39–100% sensitivity and 42–97% specificity for detecting PH [24]. Beyond high pressure
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estimates and right cavities’ dilation, several echocardiographic features can coexist in
PH, such as interventricular septum flattening, dilation of the inferior cava, and short
pulmonary artery flow acceleration time [7]. Still, as a singular method used for early
detection of PH, echocardiography can sometimes be inaccurate in evaluating PAP, over
or under-estimating it [4]. Typically, it over-estimates sPAP with more than 10 mmHg
which makes it a low efficiency screening method in mild or asymptomatic patients [24];
under-estimation is also possible especially if incomplete TR envelopes are obtained or RV
dysfunction coexists. Operator experience is of the utmost importance, PAP value being
unobtainable in 20–39% of cases [31].
Therefore, present guidelines suggest a combination of echocardiographic parameters
in order to raise suspicion of PH, especially in the grey zone of TRV between 2.8–3.4 m/s [7]
(Tables 3 and 4).
Table 3. Echocardiographic assessment of PH probability. Modified after [7]. Legend: TR–tricuspid
regurgitation, PH–pulmonary hypertension. See Table 4 for supplementary echocardiographic signs.





≤2.8 or not measurable No Low






Table 4. Supplementary echocardiographic signs suggestive of PH. Modified after [7]. Legend:
RV–right ventricle, LV–left ventricle, IVC–inferior vena cava, RA–right atrium.




acceleration time < 105 ms
and/or midsystolic notching









RA area (end-systole) >18 cm2
Pulmonary artery diameter >
25 mm
Other less used parameters in clinical practice for this aim, such as the left atrium (LA)
volume and the RV myocardial performance index, are independent predictors of PAH in
SSc patients [25]. Pulmonary pulse wave transit time (PPTt) was suggested by Wibmer
et al. to be a surrogate marker for the hemodynamic disturbances which the vascular bed
suffers in PH [58]. It was demonstrated that PPTt is low in patients with SSc compared to
healthy subjects and that it can be considered an early result of inflammatory alterations
caused by the systemic disease in the small pulmonary vessels [59]. Using speckle tracking
echocardiography, Hekimsoy et al. demonstrated that apical RV free wall strain was lower
in patients with SSc-PAH compared to those without PH (−14.6 ± 5.9 vs. −22.2 ± 7.5,
p = 0.03) [60]. This led to the conclusion that in scleroderma the apical RV free wall strain
has high specificity for PAH [60].
However, due to high intra- or inter-observer variability and lack of clear cut-off limits,
these observations cannot yet be incorporated into screening strategies.
Diagnostics 2021, 11, 1013 8 of 15
2.4.6. Exercise Testing
While detecting PH with resting echocardiography remains the essential clinical tool,
several studies suggested that in patients with SSc, an even earlier change would be
the abnormal increase in pulmonary pressures with exercise. A study of 25 cases with
normal resting PAP demonstrated reduced RV contractile reserve with exercise, suggesting
that subclinical RV dysfunction during physical stress might be a surrogate for early
pulmonary vascular disease [61]. Moreover, increments in measured sPAP on exercise
echocardiography can be followed over time, indicating the progression of pulmonary
vascular disease before overt PAH is diagnosed [62].
Therefore, exercise echocardiography can be a helpful tool in detecting early changes.
However, data regarding its use is currently limited and more studies are needed to
evaluate the usefulness of this non-invasive method.
Another potentially promising modality for screening of early SSc-PAH is cardiopul-
monary exercise testing, as demonstrated by Dumitrescu et al., which found a peak rate of
oxygen consumption (peak VO2) >18.7 mL/kg/min and nadir minute ventilation to CO2
production ratio (nadir VE/VCO2) >45.5 to be the most accurate parameters for excluding
pathologically elevated pulmonary artery pressures at diagnosis [63].
2.4.7. Pulmonary Function Tests
Pulmonary function tests (PFT) are part of the standard periodic evaluation of the
SSc patient due to ILD complications, but are also used for the early detection of PH. It is
mandatory to do PFTs once a year or earlier in case the clinical picture suffers changes [4].
Complete evaluation of pulmonary function must be achieved at patient’s first visit because
it brings valuable important information regarding two of the most prevalent types of pul-
monary disease in this population (PAH, ILD), by: lung volumes, spirometry, DLCO [22].
Steen et al. were the first to demonstrate that patients with PAH and lcSSc have
significantly lower mean DLCO, up to almost half of the predicted value, 5 years before
diagnosis [37]. DLCO < 60% of the predicted value increases the risk of PAH by more than
five times [37]. Because of this, patients with scleroderma and low DLCO are considered
to be at high risk for future development of this medical condition [31]. ItinerAir data
have shown that at a DLCO > 60% of the predicted values, specificity for excluding PAH
is high, a fact that afterwards became the base for including DLCO in any PH screening
programs, setting the threshold at <60% predicted [64]. Not only the absolute values, but
also progressive decline can be a sign for SSc-PAH.
Moreover, restrictive spiro-metric pattern (reduced total lung capacity (TLC), reduced
FVC) is a strong indicator for ILD and the ratio of FVC/DLCO > 1.6 is an independent,
strong predictor for PAH [65].
2.5. Screening Algorithms
Having all these tools for investigating the SSc patients in PAH screening, the further
question is how to best combine and use them in a cost-effective way, with the best
positive predicted value (PPV) and NPV. Several such algorithms were proposed by recent
guidelines and studies, detailed below. The essential common idea remains the indication
to actively screen patients with SSc or mixed connective tissue disease (MCTD) for PH,
without waiting for clinical signs to be the first diagnostic element. Nevertheless, additional
studies are needed to determine the most cost-effective strategy for implementing an
optimal duration and screening period [66,67] (Table 5).
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Table 5. Recommendations for the evaluation of patients with PAH and connective tissue dis-
ease. Modified after [7]. Legend: DLCO, diffusing capacity for carbon monoxide; IPAH, idiopathic
pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; RHC, right heart catheteri-
zation; SSc, systemic sclerosis.
Recommendations Class Level of Evidence Ref
In patients with PAH associated with connective
tissue disorder, the same treatment algorithm as
for patients with IPAH is recommended
I C [64]
Resting echocardiography is recommended as a
screening test in asymptomatic patients with SSc,
followed by annual screening with
echocardiography, DLCO and biomarkers
I C [64]
RHC is recommended in all cases of suspected
PAH associated with connective tissue disease
I C [57,64]
Oral anticoagulation may be considered on an
individual basis and in the presence of
trombophilic predisposition
IIa C [68,69]
2.5.1. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension
The most frequently used recommendations for PH screening arise from the 2015
ESC/ERS guidelines and are based on the presence of symptoms and TR [7,70]. Still, there
are certain limitations to this approach since in the early phases of the disease symptoms
might be absent and tricuspid insufficiency is missing in 20%–39% of cases, facts that paved
the way for the development of new algorithms [70].
In the current guidelines, positive screening implies TRV > 3.4 m/s, or between 2.8 and
maximum 3.4 m/s, with symptoms (dyspnea, syncope/presyncope, peripheral oedema)
and a supplementary echocardiographic parameter suggestive for elevated pulmonary
artery pressure (Tables 2 and 3) [70].
2.5.2. DETECT Algorithm
The DETECT study included 464 patients with SSc at increased risk for future develop-
ment of PAH (more than 3 years of disease duration since the first non-Raynaud symptom
and a DLCO < 60%) and performed systematic non-invasive testing and RHC [57]. After
multivariable analysis, a two-step screening model was proposed, making use of echocar-
diography only in those cases which were truly at high risk for PAH [57]. Figure 1 illustrates
the DETECT screening algorithm.
It is composed using 6 non-echocardiographic parameters: FVC/DLCO, telangiec-
tasias, ACA, NTproBNP, uric acid, right axis deviation on electrocardiography (ECG) [4]. If
the obtained score (calculated via an online website: detect-pah.com, last accessed on Mai
20, 2021) is higher than 300, progression towards echocardiography occurs, and based on
this result a recommendation for invasive hemodynamic assessment is issued or not [4].
The sensitivity of the DETECT algorithm is 96%, with a high NPV of 98% for the early
detection of PAH, but the clinical trial was centered around a scleroderma population at
high risk for PH (DLCO <60%) and it did not include patients with significant ILD [4].
Specificity was lower (48%), and up to 62% of cases were referred to RHC, leading to many
false positives undergoing further invasive assessment.
Yanjie Hao et al. compared the accurate predictability of DETECT 2013 with 2009
ESC/ERS guidelines and concluded that the sensitivity and NPV of DETECT are supe-
rior [70]. The advantage is represented by the fact that the former includes more variables
compared to the latter and it does not rely strictly on symptoms/TR, so it can be applied
also to those patients who do not have tricuspid insufficiency [70]. Moreover, DETECT is
not validated for cases with DLCO > 60%.
Diagnostics 2021, 11, 1013 10 of 15
Figure 1. DETECT Algorithm. Modified after [57]. Legend: FVC forced vital capacity; DLCO
diffusing capacity for carbon monoxide; NTproBNP, N-terminal pro-brain natriuretic peptide; RA,
right atrium.
2.5.3. ASIG Algorithm
The Australian Scleroderma Interest Group (ASIG) algorithm uses a different set of
parameters, combining NTproBNP (with a cutoff of 210 pg/mL) and PFT (assessment of
FVC/DLCO with a cutoff of 1.8). If any of these two parameters is found to be abnormal,
the patient is further referred for echocardiography and possibly RHC [71].
ASIG was published shortly after DETECT and the higher specificity (54.5%), NPV
(92.3%) and PPV (61.5%) compared to the ESC/ERS guidelines have been confirmed in a
validation cohort [70]. Contrary to DETECT, ASIG has higher specificity, meaning that the
rate of cases sent to RHC was lower at 12%, without missing any scenario of PH, proving




Figure 2. ASIG Algorithm. Modified after [70]. Legend: FVC forced vital capacity; DLCO diffusing
capacity for carbon monoxide; NTproBNP, N-terminal pro-brain natriuretic peptide.
Positive screening is considered if any of the two components (A or B) or both meet
the criteria and, in order for it to be negative, none of the criteria must be met [70].
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2.5.4. Other Screening Algorithms
Table 6 presents three other screening strategies for estimating the probability of a
patient developing PH. However, less data regarding their sensibility and predictive values
are available.
Table 6. Other PH screening methods. Modified after [72–74].
Di (distance) BO (Borg)
SA (SpO2)–DIBOSA [72]

















1–between 1 and 10
2–more than 10
Result








For every 10 points,
mPAP had a mean
elevation of 10.9 mmHg
2.6. Screening Strategies–Are They All the Same?
In a screening program, the most important performance measures are sensitivity
and NPV, as their high values announce the high ability of a strategy to capture all
affected patients.
A study by Hao et al. compared the three most utilized screening algorithms, DETECT,
ASIG and ESC/ERS 2009 guidelines, in 73 SSc patients [70]. They demonstrated that both
DETECT and ASIG had higher sensitivity and NPV compared to the ESC/ERS algorithm.
Being multiparametric, they outperformed the echocardiographic algorithm by also being
applicable in patients without a measurable tricuspid gradient. The DETECT and ASIG
algorithms seemed comparable (sensitivity 97.4% and 95.8%, respectively; NPV 92.3% for
both). The ASIG strategy might appear as less costly as it only involves two parameters.
3. Conclusions
PH in SSc is the result of several phenotypes, part of groups 1, 2, 3 or 4 in the PH
classification, and even a combination of these. Current investigations do not always
discriminate well between different forms of SSc associated PH, making management
choices more difficult.
There is a clear consensus on the recommendation that all patients with SSc or MTCD
with SSc-features should undergo active and periodic PH screening, because early diagnosis
of this complication allows timely vasodilator therapy and better prognosis. Therefore,
a local screening algorithm should be established; based on this, all patients with SSc
with positive non-invasive testing for PH must be referred to an expert center, in order to
undergo RHC and further therapeutic decisions.
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